MuSK-MG—New Clinical Study

A new clinical study has begun to evaluate the safety and efficacy of amifampridine phosphate treatment in patients with MuSK-antigen positive myasthenia gravis (MG). For more information, please contact Catalyst or call 1-844-347-3277. Learn...

Introducing CMS001 Clinical Study

Patients with certain types of genetically confirmed congenital myasthenic syndromes (CMS) can help Catalyst evaluate the safety and effectiveness of amifampridine phosphate for the treatment of this condition. If you are unsure of your CMS diagnosis, genetic...

Expanded Neurological Pipeline

Catalyst Pharmaceuticals is studying amifampridine phosphate in a number of neurological orphan indications, such as LEMS, CMS, and MuSK-MG.  Other pipeline programs include CPP-115, which is under investigation in several neurological conditions, such as epilepsy,...

Announces Closing of Previously Announced Public Offering

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 16,428,572 shares of its common stock in the offering, which included 2,142,857 shares that were...

Announcing the Enrollment of a New Phase 2 Study for SMA

Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people...